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ABSTRACT
Zika virus (ZIKV) is a vectorborne infectious agent of global 
public health significance due to its potential to cause 
severe teratogenic outcomes. The question of whether 
health systems should consider adopting screening 
programmes for ZIKV infections during pregnancy 
warrants consideration. In this analysis, we apply the 
Wilson- Jungner framework to appraise the potential 
utility of a prenatal ZIKV screening programme, outline 
potential screening strategies within the case- finding 
pathway, and consider other epidemiological factors 
that may influence the planning of such a screening 
programme. Our evaluation of a potential prenatal ZIKV 
screening programme highlights factors affirming its 
usefulness, including the importance of Congenital Zika 
Syndrome as a public health problem and the existence 
of analogous congenital prenatal screening programmes 
for STORCH agents (syphilis, toxoplasmosis, others (eg, 
human immunodeficiency virus, varicella- zoster virus, 
parvovirus B19), rubella, cytomegalovirus, and herpes 
simplex virus). However, our assessment also reveals key 
barriers to implementation, such as the need for more 
accurate diagnostic tests, effective antiviral treatments, 
increased social service capacity, and surveillance. Given 
that the reemergence of ZIKV is likely, we provide a guiding 
framework for policymakers and public health leaders that 
can be further elaborated and adapted to different contexts 
in order to reduce the burden of adverse ZIKV- related birth 
outcomes during future outbreaks.
INTRODUCTION
Screening programmes are a core public 
health service and can be a valuable tool in 
improving a population’s health outcomes.1 
The purpose of screening is to identify indi-
viduals in a ‘healthy’ population who are at 
higher risk of a specific health condition, in 
order to provide early treatment and/or inter-
vention to high- risk individuals and thereby 
reduce the incidence of and/or mortality 
due to the condition in the full population.1 
Prenatal screening programmes for congen-
ital conditions, including those caused by 
infectious diseases like Zika virus (ZIKV), 
aim for the early detection of risk factors for 
fetal anomalies in order to enable expectant 
parents to make informed choices about their 
pregnancy and aftercare.1
Similar to other STORCH (syphilis, toxo-
plasmosis, others [eg, HIV, varicella- zoster 
virus, parvovirus B19], rubella, cytomega-
lovirus and herpes simplex virus) agents, 
ZIKV can be vertically transmitted across the 
placenta during pregnancy with potentially 
Summary box
 ► While it is well established that Zika virus (ZIKV) 
infections during pregnancy can have deleterious 
impacts on the health and well- being of congenitally 
infected offspring and their families, the question of 
whether prenatal screening for ZIKV may be war-
ranted during epidemics remains open.
 ► Our analysis of a potential prenatal ZIKV screening 
programme using the Wilson- Jungner framework 
highlights factors affirming the utility of screening, 
such as the importance of Congenital Zika Syndrome 
as a public health problem, a growing understanding 
of the natural history of the disease, and the likely 
acceptability of a programme.
 ► However, our assessment also reveals key barriers 
to implementation, especially related to diagnostics, 
antiviral treatments, social service capacity, and 
surveillance.
 ► Adopting prenatal screening for ZIKV during an 
epidemic would enable pregnant persons to make 
more informed decisions about their pregnancy 
and facilitate the early identification of exposed 
newborns for specialised follow- up care, which 
may be of particular importance for children who 
present asymptomatically at birth but develop 
ZIKV- related sequelae in later childhood.
 ► Nevertheless, to be most impactful, prenatal 
screening programmes require cheaper and more 
precise ZIKV screening tests, as well as continued 
investment in the development of efficacious and 
safe therapeutics.
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deleterious consequences for fetal development. Unlike 
other STORCH agents, ZIKV is vectorborne, and its 
transmission by competent Aedes spp. mosquitoes2 can 
facilitate explosive outbreaks with spatial and temporal 
clustering of neonates born with Congenital Zika 
Syndrome (CZS).3–5 As of July 2019, a total of 87 coun-
tries and territories across Africa, the Americas, South- 
East Asia and the Western Pacific reported evidence of 
autochthonous mosquitoborne transmission of ZIKV, 
while an additional 61 countries and territories have 
demonstrated evidence of established Aedes spp. vectors 
without yet having documented ZIKV transmission.6
Given the severity of outcomes associated with congen-
ital ZIKV infection and the threat of ZIKV reemergence in 
areas with prior outbreaks or emergence in new settings,7 
the adoption of a screening programme for ZIKV infec-
tions during pregnancy warrants consideration. Here, 
we draw on the Wilson and Jungner evaluative frame-
work8 to analyse the feasibility and appropriateness of a 
prenatal screening programme during a ZIKV epidemic 
(summarised in table 1).
CONSIDERATIONS FOR ASSESSING A PRENATAL SCREENING 
PROGRAMME FOR ZIKV INFECTION
1. The condition sought should be an important health 
problem
Whereas maternal ZIKV infections are generally mild and 
self- limiting, a subset of congenital ZIKV infections may 
disrupt fetal development and result in structural malfor-
mations and functional neurodevelopmental impair-
ments, which are collectively recognised as CZS.9–11 
Although there is a wide spectrum of CZS severity, chil-
dren with more severe cases of CZS are likely to have 
long- term needs for caregiving, medication and special-
ised support, which can incur substantial social and 
economic costs for affected individuals, their families 
and wider society.12 Additionally, evidence from a nation-
wide retrospective study linking routinely collected data 
in Brazil from 2015 to 2017 reported a case fatality rate 
of 9.4% (95% CI: 8.4% to 10.6%) among children with 
confirmed CZS diagnoses, with more than 90% of deaths 
occurring in infancy.13
2. There should be a suitable test or examination
ZIKV infections during pregnancy are primarily iden-
tified using nucleic acid amplification and serological 
tests. Nucleic acid amplification tests detect the presence 
of ZIKV RNA (ie, indicating acute infection) by reverse 
transcription- polymerase chain reaction (RT- PCR) in 
maternal whole blood, serum, plasma, urine and amni-
otic fluid in patients presenting, in general, <7 days from 
onset of symptoms, and serological tests detect binding 
and neutralising antibodies (ie, indicating acute or prior 
infection) against specific ZIKV antigens (eg, NS1) in 
whole blood, serum and plasma in patients presenting 
≥7 days from symptom onset.14 Ideally, a combination 
of the high specificity of molecular testing and the high 
sensitivity of serological testing for ZIKV would poten-
tially allow for the most accurate identification of infec-
tions.15 While individual assay performances are highly 
variable and can depend on the type and timing of 
sample collected and, in the case of serological assays, 
the immunological cross- reactivity with other flaviviruses 
(eg, dengue virus (DENV)), the overall performances 
of ZIKV- specific assays are largely similar to the perfor-
mances of routine diagnostic tests for other STORCH 
agents during pregnancy.16 Integrating ZIKV into the 
STORCH screening paradigm has the potential to 
improve standardisation and the differential diagnosis of 
other congenital infections.
3. The natural history of the condition, including development 
from latent to declared disease, should be adequately 
understood
The generally mild clinical presentation and the co- cir-
culation of other immunologically cross- reactive flavi-
viruses in ZIKV- endemic areas has made establishing a 
case definition for ZIKV infection in pregnant persons 
challenging.15 A series of population- based prospective 
cohort studies (table 2) provide evidence that among 
pregnant individuals with laboratory- confirmed ZIKV, 
the risk of congenital ZIKV infection ranged between 5% 
and 35%, and the risk of adverse pregnancy and birth 
outcomes ranged between 2% and 46%,17–25 66 with the 
high variability in adverse risk estimates due, in part, 
to the differing lengths of follow- up and outcome defi-
nitions used between studies. Children with CZS who 
survive infancy are expected to have a prognosis compa-
rable with that of others who have conditions associated 
with microcephaly, epilepsy, and intellectual disability.26
4. There should be a recognisable latent or early symptomatic 
stage
While highly sensitive and specific laboratory diagnostic 
assays will improve the identification of maternal ZIKV 
infection before the onset of severe fetal anomalies, there 
is currently no available antiviral for impeding vertical 
transmission of ZIKV in humans27 or methods to accu-
rately identify those fetuses who may be ZIKV- exposed 
but uninfected. Another complicating factor in recog-
nising pregnancies at risk is the large fraction of asymp-
tomatic ZIKV infections,28 which are reported to have a 
similar likelihood of adverse birth outcomes as sympto-
matic infections.29
5. The test should be acceptable to the population
While further research on attitudes of expectant fami-
lies in relation to ZIKV screening is needed, non- invasive 
prenatal screening tests for congenital infections are 
generally well accepted.30 31 A study in Malaysia found 
that 81.8% of pregnant individuals who attended ante-
natal care were willing to be tested for ZIKV, with the 
lowest percentage found in those in the third trimester.32 
Effective antenatal education on the various benefits 
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Table 1 Summary of points supporting and not supporting each criterion of the Wilson and Jungner screening framework, 
with additional recommendations for futher research and/or public health actions
Criteria
Points supporting the 
criterion
Points not supporting the 
criterion
Recommendations for further 
public health action(s) and/or 
research
1. The condition sought 
should be an important health 
problem
 ► ZIKV infection during 
pregnancy may lead to 
cases of CZS, which can 
pose a significant burden 
at the individual, family, 
and societal level.
 ► ZIKV infection during 
pregnancy occurs at a 
lower frequency between 
outbreaks in areas with 
arbovirus circulation.
 ► Public health surveillance for 
ZIKV epidemics to inform the 
timing and type of prenatal 
ZIKV screening programme.
 ► Research on the long- term 
health, social and economic 
impacts of CZS on affected 
children, families, and 
communities.
2. There should be a suitable 
test or examination
 ► Validated and acceptable 
molecular and serological 
tests for detecting 
ZIKV infections during 
pregnancy are currently 
available.
 ► Molecular tests have 
narrow windows of 
detection.
 ► Serological tests are 
subject to immunological 
cross- reactivity with other 
flaviviruses.
 ► Combining highly specific 
molecular tests and highly 
sensitive serological tests 
to allow for more accurate 
identification of ZIKV 
infections.
 ► Research to develop 
diagnostic tests with enhanced 
sensitivity and specificity.
 ► Research to evaluate 
performance of tests in 
settings with endemic flavivirus 
circulation.
3. The natural history of 
the condition, including 
development from latent to 
declared disease, should be 
adequately understood
 ► Children with CZS who 
survive infancy are 
expected to have a 
prognosis comparable 
with children who 




 ► Significant heterogeneity 
remains in the risk 
estimates of adverse 
outcomes associated 
with prenatal ZIKV 
exposure, in part due 
to inconsistencies in 
the range of outcomes 
assessed.
 ► The prognosis of 
children with prenatal 
ZIKV exposure remains 
uncertain beyond 5 years 
of age.
 ► Expansion of infrastructure 
and governance policies 
for sustained data sharing 
between Zika cohort studies.
 ► Research using individual 
participant data meta- analyses 
of pregancy and paediatric 
cohorts and standardised 
outcomes to improve the 
precision of risk estimates.
 ► Research using paediatric 
cohort studies and linked 
electronic health records 
to follow up children with 
prenatal ZIKV exposure born 
with or without apparent 
manifestations of CZS.
4. There should be a 
recognisable latent or early 
symptomatic stage
 ► Sensitive and specific 
laboratory diagnostic 
assays have the potential 
to detect maternal ZIKV 
infections before the 
onset of severe fetal 
anomalies.
 ► Antivirals for impeding 
vertical transmission of 
ZIKV are not currently 
available.
 ► Prenatal and postnatal 
testing to identify 
offspring who may 
be ZIKV- exposed but 
uninfected remains 
limited.
 ► A large portion of 
ZIKV infections are 
asymptomatic.
 ► Public health efforts to improve 
antenatal care attendance.
 ► Monitoring of children with 
prenatal ZIKV exposure who 
present asymptomatically at 
birth for developmental delays 
and late- onset sequelae of 
congenital infections.
 ► Research to develop antiviral 
treatments to block vertical 
transmission.
 ► Research to improve the safety 
and effectiveness of testing for 
offspring infection status (eg, 
via amniocentesis or neonatal 
serum/urine testing).
Continued
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Criteria
Points supporting the 
criterion
Points not supporting the 
criterion
Recommendations for further 
public health action(s) and/or 
research
5. The test should be 
acceptable to the population
 ► Non- invasive prenatal 
screening tests for 
STORCH agents are 
generally well accepted.
 ► There is limited research 
on the attitudes towards 
prenatal screening tests 
for ZIKV.
 ► Public health education and 
communication on risks of 
prenatal ZIKV infections and 
screening methods.
 ► Research on attitudes of 
expectant families in ZIKV- 
endemic settings.
6. There should be an agreed 
policy on whom to treat as 
patients
 ► Both the pregnant person 
and offspring would be 
considered as patients 
due to the potential for 
vertical transmission of 
ZIKV infection during 
pregnancy.
 ► Local policies may differ 
with regards to the rights 
of pregnant persons and 
their offspring (eg, with 
respect to pregnancy 
terminations).
 ► Prenatal counselling following 
positive screening test result.
 ► Postnatal clinical and social 
support for children with 
prenatal exposure to ZIKV and 
their families.
 ► Research to evaluate indirect 
effects of CZS on caregivers’ 
mental health, social support, 
and lived experiences.
7. There should be an 
accepted treatment for 
patients with recognised 
disease
 ► Anticipatory guidance 
to caregivers and early 
referrals to appropriate 
specialists and early 
intervention programmes 
for the affected child and 
family is well accepted.
 ► There are no available 
vaccines or antiviral 
treatments.
 ► Access to unrestricted 
legal abortion remains 
rare in many settings 
where ZIKV is endemic.
 ► Expanded access to 
specialised treatment 
programmes for children with 
CZS.
 ► Research to develop vaccines 
to prevent ZIKV infection 
during pregnancy.
 ► Research to develop antiviral 
treatments to prevent vertical 
transmission.
8. Facilities for diagnosis and 
treatment should be available
 ► Diagnostics and 
expertise developed 
during the last ZIKV 
epidemic exist.
 ► Utilisation of existing ZIKV 
diagnostic assays require 
significant resources.
 ► Follow- up care for CZS 
patients and their families 
requires long- term 
financial commitment 
from health systems.
 ► Public health efforts to improve 
accessibility and affordability 
of tests.
 ► Research to develop rapid, 
low- cost, point- of- care testing.
 ► Research into effectiveness 
of interventions in clinically 
relevant subgroups to inform 
targeted treatment.
9. The cost of case finding 
should be economically 
balanced in relation to possible 
expenditure on medical care 
as a whole
 ► Screening is likely to 
be most cost- effective 
during an outbreak 
situation.
 ► In non- outbreak 
situations, screening may 
not be cost- effective, as 
screening costs could be 
more than the preventable 
costs.
 ► Enhancing capacity to rapidly 
integrate ZIKV screening 
into existing prenatal testing 
platforms during outbreak 
situations.
 ► Research to develop multiplex 
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and risks of a ZIKV screening programme may further 
increase public acceptance.
6. There should be an agreed policy on whom to treat as 
patients
Due to the potential for vertical transmission of ZIKV 
infection during pregnancy, both the pregnant person 
and offspring would be considered as patients. While 
evaluations, clinical decision making and treatment after 
birth are mainly focused on the offspring, it is crucial to 
recognise the unique vulnerabilities of parents of CZS 
patients, such as the increased risk of developing anxiety 
and depression.33
7. There should be an accepted treatment for patients with 
recognised disease
At present, there are no available vaccines to prevent 
maternal infections or approved antiviral treatments to 
limit ZIKV infection or block vertical transmission and 
acute clinical care for ZIKV infection in pregnancy is 
mainly focused on treating maternal symptoms with 
analgesics and antipyretics.34 In the absence of specific 
antiviral treatments, the screening programme would 
aim to counsel expectant parents on CZS- related risks 
and clinical decisions including, in certain settings, the 
option of elective termination of the pregnancy, as is the 
case for cytomegalovirus,35 36 and to identify prenatally 
ZIKV- exposed children for further monitoring and/or 
treatment for CZS.
Of note, access to unrestricted legal abortion remains 
rare in Latin America, with the majority of countries 
having complete prohibition or restrictive laws. Thus, 
termination is not an option for many pregnant individ-
uals with ZIKV infection, even if microcephaly and/or 
brain abnormality are detected at ultrasound examina-
tion or ZIKV is detected early in the pregnancy. However, 
there are other interventions that can be offered to 
pregnant persons and their families, such as supportive 
measures to mitigate the emotional impact of the poten-
tial adverse outcomes.37
For newborns with CZS, anticipatory guidance to 
caregivers and early referrals to appropriate specialists 
and support groups is crucial. Although confirmatory 
research is ongoing, early intervention programmes 
addressing CZS are well accepted and expected to result 
in an overall improved functional performance.38
8. Facilities for diagnosis and treatment should be available
In the absence of authorised point- of- care rapid tests,39 
ZIKV diagnostics rely on expensive, high- complexity and 
time- intensive diagnostic RT- PCR and serological assays 
requiring skilled technicians, laboratory facilities and 
specialised equipment. Further, adequate follow- up care 
for ZIKV- exposed pregnancies and tertiary care for chil-
dren with severe manifestations of CZS (eg, severe micro-
cephaly) requires significant on- going financial commit-
ment from public health systems.
9. The cost of case finding should be economically balanced 
in relation to possible expenditure on medical care as a whole
The cost of a prenatal infection screening programme 
depends on the annual number of pregnancies, whereas 
the preventable costs depend on the maternal infection 
rate. Thus, if the screening costs are less than the prevent-
able costs, then a screening programme will be cost- 
effective and should be adopted.40 This is likely to be the 
case during a ZIKV outbreak, when local maternal infec-
tion rates would be increased and the positive predictive 
value (PPV) of testing would be at its optimal.
10. Case finding should be a continuing process and not as a 
once-and-for-all project
Continuing examinations allow a programme to become 
more efficient and economical, and regular offers of 
Criteria
Points supporting the 
criterion
Points not supporting the 
criterion
Recommendations for further 
public health action(s) and/or 
research
10. Case finding should be a 
continuing process and not as 
a once- and- for- all project
 ► Ultrasound may be 
used with or in lieu of 
laboratory testing to 
detect cases of CZS.
 ► Routine paediatric 
evaluations and 
developmental screening 
may be used to detect 
CZS- related anomalies at 
a later stage.
 ► Maternal ZIKV infections 
may be asymptomatic, 
and ZIKV- exposed infants 
may present without 
typical CZS features.
 ► Increased monitoring of 
pregnancies during an 
outbreak situation.
 ► Continued monitoring 
of symptomatic and 
asymptomatic children with 
prenatal ZIKV exposure 
for developmental delays 
and late- onset sequelae of 
congenital infections.
 ► Research evaluating paired 
mother- offspring testing to 
detect congenital infections 
postnatally.
CZS, Congenital Zika Syndrome; STORCH, (syphilis, toxoplasmosis, others (eg, human immunodeficiency virus, varicella- zoster virus, 
parvovirus B19), rubella, cytomegalovirus, and herpes simplex virus); ZIKV, Zika virus.
Table 1 Continued
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examination are likely to gradually cover more and more 
of the population at risk. In addition to or in lieu of labo-
ratory testing, continued monitoring and case finding 
of at- risk pregnant individuals can be done using ultra-
sound. Although microcephaly was initially described as 
the hallmark feature of in utero exposure to ZIKV infec-
tion and presentation of CZS at birth,41 it is now well 
accepted that newborns can have CZS in the absence of 
microcephaly.42 43 Notably, head circumference (HC) 
may be increased in some cases due to severe ventricu-
lomegaly.44
Given reports of late- onset ZIKV- associated anomalies 
among children with a normal HC at birth,45 it is recom-
mended that healthcare providers remain vigilant for 
possible sequelae of congenital infection46 even in the 
absence of typical phenotypic features of CZS.47 The 
US Centers for Disease Control and Prevention recom-
mends laboratory testing of infants with clinical features 
of CZS regardless of maternal laboratory results, as well 
as ZIKV- exposed infants without CZS features.46 While 
the specific clinical evaluation and management of CZS 
depends on the ZIKV status of the infant and/or mother, 
it is recommended that a cranial ultrasound, as well as 
audiology and ophthalmology assessments are performed 
by 1 month of age.46 Follow- up for 6 months to 1 year is 
also advised to assess for the development of any later 
onset clinical manifestations that could be associated 
with CZS (eg, epilepsy, developmental delays or delay in 
head growth)46 and to facilitate prompt referral to appro-
priate specialists, and early intervention programmes if 
required.46
PRENATAL ZIKV SCREENING IN PRACTICE: BENEFIT VERSUS 
HARM
A major challenge in implementing a screening 
programmes is balancing the benefits with the harms 
of screening.1 The benefit of prenatal screening for 
ZIKV during an epidemic would be implementation 
of early interventions that can better support families 
by providing parents with information to help make 
informed choices, as well as providing newborns with 
specialist care. There are also societal benefits of an ante-
natal screening programme such as the potential costs 
saved by preventing long- term disabilities. A screening 
programme could also drive positive changes in a health 
system that provides better overall support for families 
who care for children with congenital disabilities, as well 
as potentially driving research for improved diagnostic 
testing and antiviral treatments. Additional benefits of 
prenatal screening for congenital infections include an 
opportunity to educate seronegative individuals about 
behaviours that increase risk of transmission.48 For 
example, a study in France showed improved hygiene 
education for expectant mothers and their partners 
reduced cytomegalovirus infection rates during the preg-
nancy.49
As there will always be false positives and false nega-
tives, a screening programme may introduce unintended 
harms.1 Whereas false- negative tests (ie, low sensitivity) 
will lead to missed opportunities for further evaluation 
and delayed detection of CZS,50 false- positive tests (ie, 
low specificity) have the potential to lead to adverse 
outcomes including potentially unwarranted preg-
nancy terminations. A screening test’s PPV and negative 
predictive value (NPV) (ie, the probability that subjects 
with a positive or negative screening result truly do or 
do not have the condition, respectively) depend not 
only on the sensitivity and specificity of the screening 
test but also on the prevalence of the condition in the 
population. In a population with low ZIKV circulation, 
screening would result in a high proportion of false 
positives requiring further invasive confirmatory testing, 
which brings additional risks to the fetus and mother, 
as well as the potential psychosocial repercussions that 
need to be considered.51 In addition to the impact on 
the individual/family, the economic costs of screening 
to a country’s health system is also important, especially 
if the majority of individuals being screened do not have 
the condition.
Another factor that complicates the benefit–harm 
analysis is the current uncertainty in the estimated risk 
of adverse outcomes following detection of a ZIKV infec-
tion during pregnancy, which may challenge the clinical 
decision- making process and be a source of significant 
anxiety to expectant parents. Given that only limited 
quantities of new data are likely to become accessible 
before the next reemergence of ZIKV, large- scale indi-
vidual participant data meta- analyses of existing cohort 
studies, such as those proposed by the Zika Brazilian 
Cohorts Consortium,52 the European Commission Zika 
Consortia Vertical Transmission Study Group53 and the 
Zika Virus Individual Participant Data Consortiun,37 54 
will be essential for standardising exposure and outcome 
definitions and improving understanding of the full 
spectrum of CZS outcomes including rare outcomes, the 
precision of risk estimates, and the sources of heteroge-
neity in the risk estimates. In addition, efforts to link the 
longitudinal electronic health records (eg, hospitalisa-
tions and deaths) of children in ZIKV- affected regions, 
such as through the Centro de Integração de Dados e 
Conhecimentos para Saúde Birth Cohort in Brazil,55 will 
yield valuable insights regarding the long- term prognosis 
of children with CZS.
Ultimately, the decision to implement a prenatal 
ZIKV screening programme is highly dependent on the 
context of a country’s health system, resources available 
and guiding ethical principles. Screening criteria that 
incorporate the values and priorities of a country and 
its population may help balance the benefits and harms 
of a screening programme. Anticipated benefits and 
harms can be tested using pilot projects, which will also 
generate important data about cost- effectiveness and effi-
ciency. Additional research that more precisely defines 
risk estimates of adverse fetal outcomes or leads to the 
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development of lower cost and/or more accurate diag-
nostics or of novel therapeutics will also likely tip the 
scale.
POTENTIAL STRATEGIES FOR PRENATAL ZIKV SCREENING 
DURING AN OUTBREAK
To help illustrate population- based prenatal screening 
for ZIKV, here, we present a general flow- diagram with 
recommended components that can be further elabo-
rated to fit each settings’ needs and available resources. 
In settings with a history of recent ZIKV circulation and a 
high seroprevalence, a universal screening strategy based 
on serological testing at the first antenatal visit could be 
adopted to identify seronaive individuals who may be at 
heightened risk of ZIKV infections and would benefit 
from repeated testing during pregnancy (figure 1; 
option 1). The chief limitations of this approach are 
cross- reactivity with DENV and other flaviviruses56 as well 
as false reassurance and reduced preventive behaviours 
and prenatal monitoring.15 An alternative approach for 
universal screening would be to test all pregnant individ-
uals near the end of the first trimester using a combina-
tion of serological and molecular assays to detect recent 
and acute infections (option 2). While testing could be 
repeated during the second or third trimester, current 
evidence suggests maternal infection during the first 
trimester is associated with the highest risk of CZS and 
vertical transmission,19 39 57 and the option of elective 
Figure 1 Potential ZIKV screening strategies during pregnancy. This flow chart illustrates the progression for different CZS 
screening strategies during pregnancy with options for increased confirmatory testing depending on resources available.65 
CZS, Congenital Zika Syndrome; GA, gestational age; IgM, immunoglobulin M; PRNT, plaque reduction neutralisation test; RT- 
PCR, reverse transcription- polymerase chain reaction; ZIKV, Zika virus.
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pregnancy termination remains available in some, but 
not all, countries. Lastly, ZIKV screening via molecular 
testing could be targeted to pregnant individuals who 
present with symptoms consistent with acute ZIKV infec-
tion (option 3). Although targeting only symptomatic 
individuals can help reduce operating costs, more than 
60% of ZIKV infections that are asymptomatic may be 
missed.28 A potential strategy that can be added to option 
3 to reduce cost and to cover asymptomatic infections, 
is to pool asymptomatic samples before RT- PCR with 
workup of individual samples only if pooled test results 
are positive. This has been used with sufficient diag-
nostic accuracy for SARS- CoV-2 with pool sizes up to 30 
samples.58
Modification to the diagram may be warranted in 
settings with mostly travel- related infections. ZIKV sero-
prevalence varies hugely among traveller populations 
compared with resident populations living in areas with 
active transmission (<2% in travellers vs up to 60% in 
the local population,16 due to differing risks of expo-
sure as well as access to and affordability of preventive 
measures.59 For settings with mostly travel- related trans-
mission, a routine questionnaire, which is recommended 
by the American College of Obstetricians and Gynecolo-
gists to identify possible exposure before considering the 
need for testing,60 can be applied first to identify those at 
risk before initiating any of the options presented.
Following a positive screening result, an ultrasound 
should be obtained as evidence suggests a normal HC 
to femur length ratio in fetuses without microcephaly is 
associated with an 87% NPV for the postnatal detection 
of congenital ZIKV- associated injuries.61 Further labora-
tory testing to determine offspring infection status can 
be performed either before (via amniocentesis, which 
may introduce additional risks to the pregnancy and 
for which data regarding PPV and NPV are unknown62) 
or as soon as possible after birth (using serum and/ or 
urine).24 62 In addition to standard evaluations, all infants 
with known prenatal exposure to ZIKV infection should 
also receive a head ultrasound, an opthalmological 
examination, and a hearing examination. Lastly, infants 
with laboratory or clinical evidence of CZS should have 
referrals to early intervention service programmes and 
family support services in addition to clinical consulta-
tions regarding child development, infectious disease, 
neurology, and other specialities as indicated based on 
clinical findings.62
TIMING FOR IMPLEMENTING A PRENATAL ZIKV SCREENING 
PROGRAMME
A crucial prerequisite to the effective implementation 
of a screening programme is surveillance. By systemati-
cally monitoring the incidence of infections and asso-
ciated disease, such as congenital anomalies, surveil-
lance helps to inform the timing and type of screening 
programme adopted by providing information on 
the rate of community- wide transmission. In addition, 
long- term surveillance may also yield information on the 
likely proportion of the pregnant population with pre- 
existing protective immunity to ZIKV. Although there 
is limited evidence on the duration of neutralising anti-
bodies following a ZIKV infection,63 it is plausible that, 
in populations with a high seroprevalence following an 
outbreak (eg, 63% in Salvador, Brazil),64 there may be a 
lower maternal infection rate in future epidemics. Thus, 
given the synergistic utility of screening and surveillance, 
resuming or establishing the latter may be a necessary 
preamble to effective implementation of a screening 
programme.
CONCLUSION
Designing a screening programme for ZIKV during preg-
nancy is a complex process that requires careful consid-
eration. Maternal infection is often asymptomatic or 
consists of only mild, non- specific symptoms and vertical 
transmission rates are variable but have potentially life- 
altering consequences. Normally, screening provides 
medical benefits from early treatment. However, while 
early intervention allows for anticipatory support of 
newborns and families affected by CZS, there are no 
treatments currently available to prevent the vertical 
transmission of ZIKV or to minimise the risk of poten-
tial congenital anomalies, and termination of pregnancy 
is not always a legal option. This initial assessment of 
the feasibility and utility of a prenatal ZIKV screening 
programme using the Wilson and Jungner criteria high-
lights affirmative factors such as acceptability and poten-
tial positive impact of such a programme, even in the 
absence of curative treatment and accurate diagnostics. 
In addition, consideration of the timing, as well as the 
overall benefits and harms of implementing a prenatal 
ZIKV screening programme are necessary foundations 
for more context- dependent decision making. Moving 
forward, research should be directed into the natural 
history of CZS, especially the long- term prognosis of 
ZIKV- exposed children who present with defects before 
or at birth and those who present asymptomatically at 
birth but develop clinical manifestations later on. The 
development of screening tests with enhanced precision 
and decreased costs and the introduction of efficacious, 
safe treatment will further improve the benefit- to- risk 
balance.
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